Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck KGaA's MS Drug Mavenclad May Defy Doubters

Executive Summary

The German group's oral treatment is late coming to the market but a key opinion leader believes that it will change the way multiple sclerosis is treated.

Advertisement

Related Content

Merck KGaA Foresees Mid-2019 US Launch Of Oral MS Therapy Mavenclad
Post-Rebif, Merck KGaA Keeps Faith With MS Therapies
Merck KGaA Highlights Mavenclad Advances In Tough Quarter
First In MS: Fingolimod Nears Market For Relapsing MS In Children, Adolescents
Merck KGaA Previews Cladribine Regulatory Revival Story At ECTRIMS

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC099372

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel